Medexus Pharmaceuticals Inc. (MEDXF)
OTCMKTS · Delayed Price · Currency is USD
2.080
+0.047 (2.29%)
Aug 22, 2025, 4:00 PM EDT
Medexus Pharmaceuticals Revenue
Medexus Pharmaceuticals had revenue of $24.62M in the quarter ending June 30, 2025, a decrease of -9.78%. This brings the company's revenue in the last twelve months to $105.66M, down -2.87% year-over-year. In the fiscal year ending March 31, 2025, Medexus Pharmaceuticals had annual revenue of $108.33M, down -4.18%.
Revenue (ttm)
105.66M
Revenue Growth
-2.87%
P/S Ratio
0.63
Revenue / Employee
1.16M
Employees
91
Market Cap
66.92M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 108.33M | -4.72M | -4.18% |
Mar 31, 2024 | 113.05M | 4.96M | 4.59% |
Mar 31, 2023 | 108.10M | 31.40M | 40.93% |
Mar 31, 2022 | 76.70M | -2.96M | -3.71% |
Mar 31, 2021 | 79.66M | 24.15M | 43.52% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Glass House Brands | 221.55M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 105.45M |
American Oncology Network | 1.76B |
Northwest Biotherapeutics | 1.09M |
Silence Therapeutics | 27.17M |
Global Cord Blood | 196.10M |
Medexus Pharmaceuticals News
- 10 days ago - Medexus Pharmaceuticals Inc. (MEDXF) Q1 2026 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Medexus Announces Fiscal Q1 2026 Results, Including Positive Results from US Launch of GRAFAPEX (treosulfan) for Injection - Newsfile Corp
- 18 days ago - Medexus Schedules First Fiscal Quarter 2026 Conference Call - Newsfile Corp
- 18 days ago - GRAFAPEX (treosulfan) for Injection Receives CMS Approval of New Technology Add-On Payment (NTAP) for Eligible Cases in CMS's Fiscal Year 2026 - Newsfile Corp
- 2 months ago - Medexus Pharmaceuticals Inc. (MEDXF) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Medexus Announces Strong Fiscal Year 2025 Results, Including Initial Results from Launch of GRAFAPEX (treosulfan) for Injection in the United States - Newsfile Corp
- 2 months ago - Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2025 Conference Call - Newsfile Corp
- 4 months ago - Medexus Successfully Completes Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in Quebec, Canada - Newsfile Corp